Overall, the depletion of SOS1 by SIAIS562055 increased SLC22A4 expression and facilitated the uptake of BCR–ABL inhibitors in CML, providing support for the combination therapy to achieve better anticancer efficacy and overcome resistance. Here, SLC22A4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.